PLD3: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: PLD3

NCBI ID: G23646

PLD3

PLD3: A Potential Drug Target Or Biomarker for Various Diseases

PLD3 (hindIII K4L homolog) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation, which results in the substitution of a thymine base for a guanine base at position 322, has been shown to alter the structure and function of the PLD3 gene.

PLD3 is a key regulator of DNA double-strand break repair, a critical process that helps maintain the integrity of chromosomes during cell division and repair. The PLD3 gene is located on chromosome 16 and encodes a protein known as PLD3, which is involved in the repair of double-strand breaks in DNA. PLD3 plays a crucial role in preventing errors in DNA repair, which can lead to the development of cancer.

Studies have shown that PLD3 gene mutations can result in the development of various diseases, including cancer. For example, PLD3 mutations have been identified in various types of cancer, including breast, ovarian, and colorectal cancer. The presence of PLD3 mutations has been shown to increase the risk of cancer progression and the development of invasive and metastatic forms.

In addition to its role in cancer, PLD3 has also been shown to be involved in the development of neurodegenerative diseases. The PLD3 gene has been shown to be involved in the repair of DNA double-strand breaks in the brain, which is thought to play a role in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

PLD3 has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and lupus. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and joint damage.

Despite the potential implications for a variety of diseases, the study of PLD3 gene mutations is still in its infancy. little is known about the exact role of PLD3 in disease, and more research is needed to fully understand its potential as a drug target or biomarker.

In conclusion, PLD3 (hindIII K4L homolog) is a gene that has the potential to be a drug target or biomarker for various diseases. Its unique genetic mutation, which results in the substitution of a thymine base for a guanine base at position 322, has been shown to alter the structure and function of the PLD3 gene. Further research is needed to fully understand the role of PLD3 in disease and to develop effective treatments.

Protein Name: Phospholipase D Family Member 3

Functions: 5'->3' DNA exonuclease which digests single-stranded DNA (ssDNA) (PubMed:30312375). Regulates inflammatory cytokine responses via the degradation of nucleic acids, by reducing the concentration of ssDNA able to stimulate TLR9, a nucleotide-sensing receptor in collaboration with PLD4 (By similarity). May be important in myotube formation (PubMed:22428023). Plays a role in lysosomal homeostasis (PubMed:28128235). Involved in the regulation of endosomal protein sorting (PubMed:29368044)

The "PLD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets